U.S., Nov. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07949344) titled 'A Post-Marketing Trial to Evaluate the Safety and Efficacy of Quizartinib in Chinese Participants With Newly Diagnosed FMS-like Tyrosine Kinase 3-internal Tandem Duplication [FLT3-ITD] (+) Acute Myeloid Leukemia (AML)' on Nov. 15.

Brief Summary: The clinical trial is designed to assess the safety of quizartinib in newly diagnosed FLT3-ITD (+) AML in Chinese participants.

Study Start Date: Dec. 01

Study Type: INTERVENTIONAL

Condition: Acute Myeloid Leukemia

Intervention: DRUG: Quizartinib

Participants will receive quizartinib 40 mg orally once daily for 14 days during the induction and consolidation phases and 30 mg orally onc...